Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Sofosbuvir-Velpatasvir in Adults With Hepatitis C Virus Infection and Compensated Cirrhosis in Japan.

< BACK TO ARCHIVE


2022 Jul 08


Hepatol Res


http://www.ncbi.nlm.nih.gov/pubmed/35802063?dopt=Abstract

Sofosbuvir-Velpatasvir in Adults With Hepatitis C Virus Infection and Compensated Cirrhosis in Japan.

Authors

Sofosbuvir-Velpatasvir in Adults With Hepatitis C Virus Infection and Compensated Cirrhosis in Japan.
Takehara T, Izumi N, Mochida S, Genda T, Fujiyama S, Notsumata K, Tamori A, Suzuki F, Suri V, Mercier R-C, Matsuda T, Matsuda K, Kato N, Chayama K, Kumada H
Hepatol Res. 2022 Jul 08.
PMID: 35802063.

Abstract

Protease-free regimens for chronic hepatitis C virus (HCV) infection are safe and effective for persons with either compensated or decompensated cirrhosis. We examined the efficacy and safety of sofosbuvir-velpatasvir in participants with HCV and compensated cirrhosis in Japan.
Read This Paper